ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Organogenesis Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue | $42.81M | $36.25M | $225.07M | $150.49M | $100.78M | $86.69M | $126.66M | $115.18M | $130.23M | – | – | – | 97.8% | -57.5% |
| Grant [Member] | $950.00K | $978.00K | $536.00K | $377.00K | $226.00K | $0 | $0 | $0 | $0 | – | – | – | 2.2% | +320.4% |
| Advanced Wound Care | – | – | – | – | – | $79.93M | $118.59M | $107.95M | $123.24M | $103.86M | $93.17M | $101.36M | – | – |
| Surgical & Sports Medicine | – | – | – | – | – | $6.77M | $8.07M | $7.22M | $7.00M | $6.11M | $6.49M | $7.17M | – | – |
By region
From the segment and revenue-disaggregation notes of Organogenesis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.